Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes-Reference-Cited by-同舟云学术

Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes

Published:2018-02-14 Issue: Volume:6 Page:
ISSN:2296-2646
Container-title:Frontiers in Chemistry
language:
Short-container-title:Front. Chem.

Author:

Kaushik Aman C.,Kumar Sanjay,Wei Dong Q.,Sahi Shakti

Funder

Chinese Ministry of Science and Technology

Publisher

Frontiers Media SA

Subject

General Chemistry

Reference73 articles.

1. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes;Ahrén;Nat. Rev. Drug Discov.,2009

2. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes;Augeri;J. Med. Chem.,2005

3. Toward the estimation of the absolute quality of individual protein structure models;Benkert;Bioinformatics,2011

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, characterization, and anti-cancer potential of novel p53-mediated Mdm2 and Pirh2 modulators: an integrated In silico and In vitro approach;Frontiers in Chemistry;2024-07-16

2. Computational methods and tools for sustainable and green approaches in drug discovery;Green Approaches in Medicinal Chemistry for Sustainable Drug Design;2024

3. Identification of candidate biomarkers and pathways associated with multiple sclerosis using bioinformatics and next generation sequencing data analysis;2023-12-07

4. Exploring potent aldose reductase inhibitors for anti-diabetic (anti-hyperglycemic) therapy: integrating structure-based drug design, and MMGBSA approaches;Frontiers in Molecular Biosciences;2023-11-20

5. Computer-aided drug design for virtual-screening and active-predicting of main protease (Mpro) inhibitors against SARS-CoV-2;Frontiers in Pharmacology;2023-11-07